ArticleCNS drugs2023

Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study.

Jai Perumal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.